Page 1,109«..1020..1,1081,1091,1101,111..1,1201,130..»

Turkey eager to invest in biotech – Anadolu Agency

Posted: March 9, 2020 at 2:52 am

ANKARA

Turkey's progress in the health sector is strategically critical beyond its economic significance, the Turkish president said on Saturday.

Congratulating the award recipients of the international biotechnology congress BIO Turkey in Istanbul, Recep Tayyip Erdogan in a letter stressed the importance of the pharmaceutical industry for Turkey

Erdogan underlined that the sector was the most important after the defense industry, emphasizing that during difficult times Turkey could only rely on its own production and infrastructure to survive.

"However, we have unfortunately faced veiled resistance in our steps to develop our domestic and national pharmaceutical industry and strengthen our medical device sector, just as we once had in the defense industry," he said.

Attending the ceremony, Vice President Fuat Oktay said that Turkey would act against "approaches" that sought to compel domestic ventures to move abroad even as the government attempted to bring research and development, design and production facilities into the country.

Inviting scientists, non-governmental organizations and universities to support Turkey's biotechnology initiatives, Oktay said investments in the defense, health and food industries would "not only save us from dependency but also turn Turkey into a global exporter."

Health Minister Fahrettin Koca also spoke at the ceremony, underscoring the role of partnerships between academia, industry and individual projects in training a qualified labor force.

After his speech, Koca presented a plaque of appreciation to the representatives of the congress's sponsors.

*Writing by Davut Demircan

View post:
Turkey eager to invest in biotech - Anadolu Agency

Posted in Biotechnology | Comments Off on Turkey eager to invest in biotech – Anadolu Agency

ORGANICELL REGENERATIVE MEDICINE : MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K) -…

Posted: March 9, 2020 at 2:49 am

You should read the following discussion together with our consolidatedfinancial statements and the related notes included elsewhere in this report.This discussion contains forward-looking statements, which involve risks anduncertainties. Our actual results may differ materially from those we currentlyanticipate as a result of many factors, including the factors we describe under"Risk Factors" and elsewhere in this report.

Some of the information in this section contains forward-looking statements thatinvolve substantial risks and uncertainties. You can identify these statementsby forward-looking words such as "may," "will," "expect," "anticipate,""believe," "estimate" and "continue," or similar words. You should readstatements that contain these words carefully because they:

discuss our future expectations;

contain projections of our future results of operations or of our financial

state other "forward-looking" information.

We believe it is important to communicate our expectations. However, there maybe events in the future that we are not able to accurately predict or over whichwe have no control. Our actual results and the timing of certain events coulddiffer materially from those anticipated in these forward-looking statements asa result of certain factors, including those set forth under "Risk Factors,""Business" and elsewhere in this report.

Unless stated otherwise, the words "we," "us," "our," the "Company" or "BiotechProducts Services and Research," "Organicell" in this section collectively referto Biotech Products Services and Research, Inc., a Nevada corporation, and itssubsidiaries.

We are engaged in the health care industry, principally focusing on supplyingproducts and services related to the growing field of regenerative anti-agingmedicine ("RAAM"). Our goal is to supply newly designed advanced biologicallyprocessed cellular and tissue-based products developed from internally-basedresearch and development activities and/or from other state-of-the-artRAAM-related products developed by third parties under exclusive and/orfavorable supply arrangements and to provide other related services used in thegrowing health care field of regenerative medicine ("RAAM Products"). We intendto distribute the RAAM Products and market RAAM-related services to the healthcare industry and a referral network of doctors and clinics (collectively, the"Providers").

From November 2016 to February 2018, we began operating our own laboratoryfacilities to process and distribute RAAM Products developed through tradesecrets acquired in connection with the employment of newly hired executivesduring November 2016 and March 2017. During this time, we also implemented anin-house sales force and made arrangements with newly identified independentdistributors to sell our RAAM Products. During February 2018, we sold ortransferred our laboratory facilities and all related assets ("Sale"), includingintellectual property rights, to Vera Acquisition LLC, a Utah limited liabilitycompany ("Vera"). The Company's decision to sell the assets comprising themanufacturing operations was made mostly to mitigate the substantial ongoingoperating risks associated with the operations of the manufacturing facility,including (a) lack of adequate working capital to pay wages to key executivesand to hire additional sales and manufacturing personnel and other criticallyneeded staff and to make required payments to vendors, (b) existing and newlyissued FDA guidelines released in November 2017 governing our manufacturingoperations that were projected to require significant additional capitalresources to be deployed to satisfactorily meet regulatory requirements withinspecified deadlines.

Since the Sale was completed, including the departure of several key executives,the Company had been unsuccessful in generating sufficient revenues and as aresult continued to have a lack of working capital to meet current operatingcosts, hiring of additional sales personnel, pay past due accounts payableobligations to its vendors, pay past due and/or current salaries to itsremaining management or fund potential growth opportunities.

On April 23, 2018, the Company and Management and Business Associates, LLC, aFlorida limited liability company ("MBA"), executed a Plan and Agreement ofReorganization ("Reorganization") whereby the Company agreed to issue to MBA anaggregate of 222,425,073 shares of its common stock of the Company, representingat the time a 51% of the outstanding shares of common stock of the Company onfully-diluted basis, for $0.001 per share (or an aggregate of $222,425), inconsideration for MBA's founder and Chief Executive Officer, Mr. ManuelIglesias' agreement to serve as the Company's Chief Executive Officer and amember of the Board of the Company. The Reorganization was effective as of April13, 2018 ("Effective Date").

Prior to the execution and effectiveness of the Reorganization, Mr. Iglesiasmoved from his position as Chief Executive Officer to a position as Co-Chairmanof the Board of Hygea Holdings Corp., a Florida corporation ("Hygea"), adiversified healthcare holding company that owns physician practices, ancillaryservices companies (e.g., pharmacies, therapies and diagnostic facilities),independent physician associations ("IPAs"), and other medical service entitiesthat provide seamless care to commercial, Medicare and Medicaid patients. As thenewly appointed Chief Executive Officer of the Company, Mr. Iglesias intended tobring his extensive industry experience and relationships to attract capital andindustry leaders to the Company as the Company sought to stabilize, expand andgrow the business into becoming a leading supplier of services, products andtherapies for the regenerative health care sector, including expansion into therapidly growing wellness sector, and to pursue clinical studies andcertifications for specific disease states using the expedited United StatesFood and Drug Administration ("FDA") program for regulatory approval forregenerative medicine advance therapies ("RMAT"). As part of the Company'sefforts to raise capital, the Company initiated and/or completed severalimportant corporate governance changes to simplify the Company's capitalstructure and to attract investment capital including:

1. On May 21, 2018, the Company filed a Certificate of Amendment with the

2. On May 21, 2018, the Company filed a Certificate of Amendment with the

Secretary of State of Nevada to effectuate a reverse stock split of one (1)

new share for each seventeen (17) shares issued and outstanding as of the

record date of May 21, 2018, with resulting fractional shares being rounded up

to the nearest whole number, and a reduction in the authorized shares from 750

million to 250 million (the "Reverse Split"). On June 18, the Company filed a

Certificate of Correction with the Secretary of State of Nevada to reverse the

amendments related to the Reverse Split, and will only file a new Certificate

of Amendment with the Secretary of State of Nevada to effectuate the Reverse

Split if the Reverse Split has been effectuated in the marketplace by FINRA.

The Company believes that a Reverse Split would bring value to the issued and

outstanding shares of the Company by limiting dilution of operating results by

an excessive number of shares overhanging the market. As discussed below, the

Reverse Split has not been effectuated in the marketplace by FINRA.

3. On June 14, 2018, the Company filed a Certificate of Withdrawal with the

Secretary of State of Nevada thereby withdrawing and terminating all

previously issued designations of the Company's Series A Preferred Stock and

Series B Preferred Stock. The Company cancelled the Company's authorized and

outstanding Series A Preferred Stock and Series B Preferred Stock in order to

provide investors with greater confidence in the value to the issued and

outstanding shares of the Company by limiting dilution of operating results

and limitation on preferences granted to other investors.

4. The Company reached agreement with its key executive management in connection

5. The Company reconstituted its Board of Directors and appointed an independent

outside director. Since the Reorganization, the Company has added additional

members to its Board of Directors.

On June 1, 2018, the Company submitted an Issuer Company-Related NotificationForm ("June 1 Notification Form") with the Financial Industry Regulatory Agency("FINRA") pursuant to Rule 10b-17 of the Securities Exchange Act of 1934, asamended (the "Exchange Act"), regarding the Name Change and Reverse Split.However, due to the Company's failing to have the required Exchange Act reportsfiled with the SEC at the time of the filing, FINRA did not announce oreffectuate the Name Change or Reverse Split in the marketplace. If the Companyintends to proceed with the Name Change and/or Reverse Split, the Company willbe required to submit a new Issuer Company-Related Notification Form forapproval upon the Company becoming current in its Exchange Act filings.

During February 2019, the Company began arranging to once again operate a newlaboratory facility in Miami, Florida for the purpose of performing research anddevelopment, production and manufacturing of anti-aging and cellular therapyproducts. This new laboratory facility became operational in May 2019 and duringthe same period, the Company began producing and distributing the products thatare being sold and distributed to its customers. The Company believes that thisstrategy will provide the Company with competitive advantages and greaterassurances that it can continue to comply with expected future FDA regulations.

In connection with the Company's ongoing research and development efforts andthe Company's efforts to meet compliance with current and anticipated UnitedStates Food and Drug Administration ("FDA") regulations expected to be enforcedbeginning in November 2020 pertaining to marketing traditional biologics andhuman cells, tissues and cellular and tissue based products that fall underSection 351 of the Public Health Services Act ("HCT/Ps"), the Company appliedfor and on July 14, 2019, the Company received Institutional Review Board("IRB") approval to proceed with two pilot studies in connection with theCompany's efforts to obtain Investigation New Drug ("IND") approval from the FDAand commence clinical trials in connection with the use of the Company'sproducts and related treatment protocols for specific indications. The Companyis aggressively pursuing efforts to obtain the aforementioned IND approvals andcommence and complete those clinical studies as well as obtaining approval tocommence additional studies for other specific indications it has identifiedthat the use of its products will provide more favorable and desired healthrelated benefits for patients seeking alternative treatment options than arecurrently available. The ability of the Company to succeed in these efforts issubject to the Company having sufficient available working capital to fund thesubstantial costs, which the Company currently does not have, and ultimately theapproval from the FDA.

On September 24, 2019, due to the Company's limited success since theReorganization in stabilizing revenues and the growing urgency for the Companyto remain compliant and meet the anticipated new and more stringent regulatorydeadlines to be imposed by the FDA in connection with the Company's products andoperations that were previously announced to go into effect in November 2020,the Board determined that it would require the services of a full-time CEO withthe requisite expertise and experience to lead the Company as it (a) movesforward with its strategy to expand its research and development efforts andsubmit IND applications for FDA approval to commence clinical trials for itsproducts to assure that the Company, its operations and its products remaincompliant with FDA regulations and (b) implements additional strategies tominimize the potential impact in the future on sales of its products as a resultof future changes in FDA regulations and/or restrictions associated withclinical trials that are utilizing the products that are currently being sold bythe Company. Accordingly, the Board voted to remove Manuel Iglesias from hisposition as CEO of the Company, although he remains as non-executive Chairman ofthe Board and a director and has been offered an alternative senior managementposition with the Company. The Board also authorized management to proceed witha search for a full-time CEO and management has identified and has beguninterviewing potential candidates.

As of October 31, 2017, Mint Organics had not been successful in obtaining aFlorida license allowing Mint Organics or Mint Organics Florida to operate abusiness to dispense medical cannabis. In addition, Mint Organics had exhaustedall of its working capital and Organicell was unable to identify additionalsources of working capital.

On April 6, 2018, Mr. Taddeo resigned as a member of the Board of Directors ofthe Company and as the Chief Executive Officer and member of the Board ofDirectors of Mint Organics and Mint Organics Florida. Mr. Taddeo's resignationwas due to his decision to pursue other personal objectives, particularly inlight of the ongoing lack of adequate working capital at Mint Organics todemonstrate the ability to fund a reasonable level of future cash compensationto Mr. Taddeo and the additional capital required to sustain future effortsrequired to successfully pursue obtaining a license to operate cannabisdispensaries.

The Company had since decided that it would not pursue any additional efforts toobtain licenses to operate MMTC's. During May 2019, the Company agreed toexchange the equity held by the remaining minority interest holders of MintOrganics and Mint Organics Florida and to convert all of the outstanding debt ofMint Organics into shares of common stock of the Company.

For the years ended October 31, 2018 and 2017, our RAAM-related operations werebeing conducted through the following wholly-owned subsidiaries*:

Anu Life Sciences, Inc., a Florida corporation formed with a business purpose

General Surgical Florida, Inc., a Florida corporation with a business purpose

of selling and distributing regenerative biologic therapies based on amnion

placental tissue derived products to doctors and hospitals.

Beyond Cells Corp., a Florida corporation formed with a business purpose to

provide consumers with education regarding the field of regenerative and

anti-aging and medicine and providing access to a specialized physician network

* As described above, the manufacturing operations of ANU were sold duringFebruary 2018, and the Company subsequently relied on supply arrangements withthird-party manufacturers or indirectly from distributors of third-partymanufacturers for the supply of RAAM products that were sold to Providers duringthe period February 6, 2018 through October 31, 2018.

Our MMTC exploratory activities were conducted through the below listedsubsidiaries. Effective April 6, 2018, Mr. Taddeo resigned as CEO of our MMTCsubsidiaries. The Company had since decided that it would not pursue anyadditional efforts to obtain licenses to operate MMTC's. During May 2019, theCompany agreed to exchange the equity held by the remaining minority interestholders of Mint Organics and Mint Organics Florida and to convert all of theoutstanding debt of Mint Organics into shares of common stock of the Company**.As a result, Mint Organics, Inc. and Mint Organics Florida, Inc. are presentlyinactive and have no assets:

Mint Organics, Inc., a Florida corporation with a business purpose of operating

Medical Marijuana Treatment Centers for defined MMTC licensed activities; and

Mint Organics Florida, Inc., a Florida corporation and subsidiary of Mint

Organics with a business purpose of operating Medical Marijuana Treatment

Centers for defined MMTC licensed activities within Florida.

** Mint Organics and Mint Organics Florida had previously issued minoritynon-voting equity interests which as of May 2019 are all owned by the Company.

We also have two other wholly-owned subsidiaries that are inactive:

Ethan New York, Inc., a New York corporation formed with a business purpose of

selling clothing and accessories through a retail store in New York City

("Ethan NY") and for which operations ended in June 2016; and

BD Source and Distribution, Corp., a Florida corporation ("BD Source") formed

Current and Future Operations:

Our current strategy is to achieve the following goals and milestones:

Develop and expand operations to provide for growth of our revenues for thesales and distribution of RAAM related products;

o Increase revenues for RAAM related products;

Hiring of additional in-house sales personnel

Selectively engaging independent distributors

Marketing private label products to distributors

Increasing market recognition for our Organicell brand from:

marketing and participating in industry trade shows

o Expand our sales market outside of the United States

o Increase the number of RAAM product offerings for various modalities using

proprietary processing, formulas and administration techniques

o Extending our referral network of Providers based on:

Superior product offerings

Demonstrating a realistic and executable regulatory roadmap to assure Company

and product compliance with current and anticipated FDA regulations

Developing and providing educational support to Providers regarding our

Execute on current strategy to assure the Company's ability to maintaincompliance with existing and the anticipated changes to FDA regulationsregarding the use and sale of our current products published in November 2017and expected to take effect by November 2020, as well as readiness to respond toongoing future changes to those regulations:

o Identify qualified candidates to fill the currently vacant CEO position that

have the requisite expertise and experience to lead the Company as it moves

forward with its strategy to enhance product research and development and

execute clinical trials of the Company's products, and

o Perform clinical based studies associated with the use of our products

(independently and/or in conjunction with Providers and/or Manufacturers) and

seek accelerated approval for each product application in accordance with the

21st Century Cures Act ("Cures Act") and/or through the granting of an

FDA-approved biologics application (BLA) to allow products to be lawfully

marketed and/or sold in the United States in accordance with newly established

FDA guidelines outlined in November 2017 expected to take effect by November

2020; and

o Continue to build out our lab facilities to meet expected production and

research requirements; and

o Engage high profile and industry recognized medical advisors and scientists to

More here:
ORGANICELL REGENERATIVE MEDICINE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K) -...

Posted in Regenerative Medicine | Comments Off on ORGANICELL REGENERATIVE MEDICINE : MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K) -…

Zirconium Oxide Thin Films Obtained by Atomic Layer Deposition Technol | IJN – Dove Medical Press

Posted: March 9, 2020 at 2:49 am

Aleksandra Seweryn,1 Ariadna Pielok,2 Krystyna Lawniczak-Jablonska,1 Rafal Pietruszka,1 Klaudia Marcinkowska,2 Mateusz Sikora,2 Bartlomiej S Witkowski,1 Marek Godlewski,1 Krzysztof Marycz,2,3 Agnieszka Smieszek2

1Institute of Physics, Polish Academy of Sciences, Warsaw PL-02668, Poland; 2Wroclaw University of Environmental and Life Sciences, Department of Experimental Biology, Wroclaw PL-50375, Poland; 3Cardinal Stefan Wyszynski University, Collegium Medicum, Warsaw PL-01938, Poland

Correspondence: Aleksandra SewerynPolish Academy of Sciences, Aleja Lotnikow 32/46, Warsaw PL-02668, PolandTel +48 22 116 33 99Fax +48 22 843 09 26Email aseweryn@ifpan.edu.plAgnieszka SmieszekWroclaw University of Environmental and Life Sciences, Norwida St. 27 B, Wroclaw PL-50-375, PolandTel +48 71 320 5229Fax +48 22 843 09 26Email agnieszka.smieszek@upwr.edu.pl

Introduction: The development of the field of biomaterials engineering is rapid. Various bioactive coatings are created to improve the biocompatibility of substrates used for bone regeneration, which includes formulation of thin zirconia coatings with pro-osteogenic properties. The aim of this study was to assess the biological properties of ZrO2 thin films grown by Atomic Layer Deposition (ALD) technology (ZrO2ALD).Methodology: The cytocompatibility of the obtained layers was analysed using the mice pre-osteoblastic cell line (MC3T3) characterized by decreased expression of microRNA 21-5p (miR-21-5p) in order to evaluate the potential pro-osteogenic properties of the coatings. The in vitro experiments were designed to determine the effect of ZrO2ALD coatings on cell morphology (confocal microscope), proliferative activity (cell cycle analysis) and metabolism, reflected by mitochondrial membrane potential (cytometric-based measurement). Additionally, the influence of layers on the expression of genes associated with cell survival and osteogenesis was studied using RT-qPCR. The following genes were investigated: B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), p53 and p21, as well as osteogenic markers, i.e. collagen type 1 (Coll-1), osteopontin (Opn), osteocalcin (Ocl) and runt-related transcription factor 2 (Runx-2). The levels of microRNA (miRNA/miR) involved in the regulation of osteogenic genes were determined, including miR-7, miR-21, miR-124 and miR-223.Results: The analysis revealed that the obtained coatings are cytocompatible and may increase the metabolism of pre-osteoblast, which was correlated with increased mitochondrial membrane potential and extensive development of the mitochondrial network. The obtained coatings affected the viability and proliferative status of cells, reducing the population of actively dividing cells. However, in cultures propagated on ZrO2ALD coatings, the up-regulation of genes essential for bone metabolism was noted.Discussion: The data obtained indicate that ZrO2 coatings created using the ALD method may have pro-osteogenic properties and may improve the metabolism of bone precursor cells. Given the above, further development of ZrO2ALD layers is essential in terms of their potential clinical application in bone regenerative medicine.

Keywords: ALD, zirconia-based coatings, pro-osteogenic properties, cytocompatibility, osteoblasts precursors

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the original post here:
Zirconium Oxide Thin Films Obtained by Atomic Layer Deposition Technol | IJN - Dove Medical Press

Posted in Regenerative Medicine | Comments Off on Zirconium Oxide Thin Films Obtained by Atomic Layer Deposition Technol | IJN – Dove Medical Press

Two faculty members named Innovation Fellows – University of Georgia

Posted: March 9, 2020 at 2:49 am

Faculty members Lohitash Karumbaiah and Donnie Longenecker have been selected as the University of Georgias Innovation Fellows for spring 2020 and will spend the semester learning how to successfully translate their research into marketable products.

Karumbaiah is an associate professor of regenerative medicine in the department of animal and dairy science and the Regenerative Bioscience Center. He conducts preclinical research on invasive tumors and traumatic brain injuries. He previously underwent training through the UGA I-Corps Accelerator program, aiming to create solutions for these brain-related pathologies.

Longenecker, a senior lecturer in the College of Environment and Design, studies performance improvements in the landscape architecture industry and the impact of continuing education on that performance. As an Innovation Fellow, he will convert this research into educational products determined to be of value both by industry regulators and landscape architects themselves. In partnership with the CED, Longeneckers goal is to develop and provide new educational programs to the landscape architecture industry.

Launched last fall as part of UGAs Innovation District initiative, the Innovations Fellows program aims to encourage faculty and staff to capitalize on the resources available through UGAs research commercialization office, Innovation Gateway, to pursue their interest in commercialization and product development.

I-Corps introduced me to the wealth of resources and expertise available to identify unmet needs and develop products and technologies to bridge therapeutic gaps, said Karumbaiah, whose research is currently funded by the National Institutes of Health and the National Science Foundations Engineering Research Center for Cell Manufacturing Therapies. I applied to the UGA Innovation Fellows Program on the back of this experience to continue to develop the knowledge base required to translate academic research innovations into clinically viable solutions.

Our outreach should improve when you consider that UGA is one of the largest landscape architecture programs in the U.S., and it has recently been ranked as the No. 1 place to hire landscape architecture grads by Design Intelligence Magazine, said Longenecker. Im hoping that through the process of customer discovery, developing a specific value proposition and understanding the logistics of delivery and organization, I can make our outreach efforts much more effective.

In addition to funding of up to $10,000, each Fellow will dive into a weeklong crash course on Gateways innovation curriculum, which will be followed by an eight-hour-per-week commitment to complete the program.

Our hope is to not only educate our faculty and staff on the value of the commercializing process, but also on the potential their research has for the local and global markets, said Ian Biggs, director of the startups program in Innovation Gateway. The ultimate goal is making our community and the world a safer, smarter place to live, and through the Innovation District initiative and our Innovation Fellows, UGAs one step closer to meeting that goal.

See original here:
Two faculty members named Innovation Fellows - University of Georgia

Posted in Regenerative Medicine | Comments Off on Two faculty members named Innovation Fellows – University of Georgia

Biochemical and structural cues of 3D-printed matrix synergistically direct MSC differentiation for functional sweat gland regeneration – Science…

Posted: March 9, 2020 at 2:49 am

Abstract

Mesenchymal stem cells (MSCs) encapsulation by three-dimensionally (3D) printed matrices were believed to provide a biomimetic microenvironment to drive differentiation into tissue-specific progeny, which made them a great therapeutic potential for regenerative medicine. Despite this potential, the underlying mechanisms of controlling cell fate in 3D microenvironments remained relatively unexplored. Here, we bioprinted a sweat gland (SG)like matrix to direct the conversion of MSC into functional SGs and facilitated SGs recovery in mice. By extracellular matrix differential protein expression analysis, we identified that CTHRC1 was a critical biochemical regulator for SG specification. Our findings showed that Hmox1 could respond to the 3D structure activation and also be involved in MSC differentiation. Using inhibition and activation assay, CTHRC1 and Hmox1 synergistically boosted SG gene expression profile. Together, these findings indicated that biochemical and structural cues served as two critical impacts of 3D-printed matrix on MSC fate decision into the glandular lineage and functional SG recovery.

Mesenchymal stem cells (MSCs) hold great promise for therapeutic tissue engineering and regenerative medicine, largely because of their capacity for self-renewal and multipotent properties (1). However, their uncertain fate has a major impact on their envisioned therapeutic use. Cell fate regulation requires specific transcription programs in response to environmental cues (2, 3). Once stem cells are removed from their microenvironment, their response to environmental cues, phenotype, and functionality could often be altered (4, 5). In contrast to growing information concerning transcriptional regulation, guidance from the extracellular matrix (ECM) governing MSC identity and fate determination is not well understood. It remains an active area of investigation and may provide previously unidentified avenues for MSC-based therapy.

Over the past decade, engineering three-dimensional (3D) ECM to direct MSC differentiation has demonstrated great potential of MSCs in regenerative medicine (6). 3D ECM has been found to be useful in providing both biochemical and biophysical cues and to stabilize newly formed tissues (7). Culturing cells in 3D ECM radically alters the interfacial interactions with the ECM as compared with 2D ECM, where cells are flattened and may lose their differentiated phenotype (8). However, one limitation of 3D materials as compared to 2D approaches was the lack of spatial control over chemistry with 3D materials. One possible solution to this limitation is 3D bioprinting, which could be used to design the custom scaffolds and tissues (9).

In contrast to traditional engineering techniques, 3D cell printing technology is especially advantageous because it can integrate multiple biophysical and biochemical cues spatially for cellular regulation and ensure complex structures with precise control and high reproducibility. In particular, for our final goal of clinical practice, extrusion-based bioprinting may be more appropriate for translational application. In addition, as a widely used bioink for extrusion bioprinting, alginate-based hydrogel could maintain stemness of MSC due to the bioinert property and improve biological activity and printability by combining gelatin (10).

Sweat glands (SGs) play a vital role in thermal regulation, and absent or malfunctioning SGs in a hot environment can lead to hyperthermia, stroke, and even death in mammals (11, 12). Each SG is a single tube consisting of a functionally distinctive duct and secretory portions. It has low regenerative potential in response to deep dermal injury, which poses a challenge for restitution of lost cells after wound (13). A major obstacle in SG regeneration, similar to the regeneration of most other glandular tissues, is the paucity of viable cells capable of regenerating multiple tissue phenotypes (12). Several reports have described SG regeneration in vitro; however, dynamic morphogenesis was not identified nor was the overall function of the formed tissues explored (1416). Recent advances in bioprinting and tissue engineering led to the complexities in the matrix design and fabrication with appropriate biochemical cues and biophysical guidance for SG regeneration (1719).

Here, we adopted 3D bioprinting technique to mimic the regenerative microenvironment that directed the specific SG differentiation of MSCs and ultimately guided the formation and function of glandular tissue. We used alginate/gelatin hydrogel as bioinks in this present study due to its good cytocompatibility, printability, and structural maintenance in long-time culture. Although the profound effects of ECM on cell differentiation was well recognized, the importance of biochemical and structural cues of 3D-printed matrix that determined the cell fate of MSCs remained unknown; thus, the present study demonstrated the role of 3D-printed matrix cues on cellular behavior and tissue morphogenesis and might help in developing strategies for MSC-based tissue regeneration or directing stem cell lineage specification by 3D bioprinting.

The procedure for printing the 3D MSC-loaded construct incorporating a specific SG ECM (mouse plantar region dermis, PD) was shown schematically in Fig. 1A. A 3D cellular construct with cross section 30 mm 30 mm and height of 3 mm was fabricated by using the optimized process parameter (20). The 3D construct demonstrated a macroporous grid structure with hydrogel fibers evenly distributed according to the computer design. Both the width of the fibers and the gap between the fibers were homogeneous, and MSCs were embedded uniformly in the hydrogel matrix fibers to result in a specific 3D microenvironment. (Fig. 1B).

(A) Schematic description of the approach. (B) Full view of the cellular construct and representative microscopic and fluorescent images and the quantitative parameters of 3D-printed construct (scale bars, 200 m). Photo credit: Bin Yao, Wound Healing and Cell Biology Laboratory, Institute of Basic Medical Sciences, General Hospital of PLA. (C) Representative microscopy images of cell aggregates and tissue morphology at 3, 7, and 14 days of culture (scale bars, 50 m) and scanning electron microscopy (sem) images of 3D structure (scale bars, 20 m). PD+/PD, 3D construct with and without PD. (D) DNA contents, collagen, and GAGs of native tissue and PD. (E) Proliferating cells were detected through Ki67 stain at 3, 7, and 14 days of culture. (F) Live/dead assay show cell viability at days 3, 7, and 14. *P < 0.05.

During the maintenance of constructs for stem cell expansion, MSCs proliferated to form aggregates of cells but self-assembled to an SG-like structure only with PD administration (Fig. 1C and fig. S1, A to C). We carried out DNA quantification assay to evaluate the cellular content in PD and found the cellular matrix with up to 90% reduction, only 3.4 0.7 ng of DNA per milligram tissue remaining in the ECM. We also estimated the proportions of collagen and glycosaminoglycans (GAGs) in ECM through hydroxyproline assay and dimethylmethylene blue assay, the collagen contents could increase to 112.6 11.3%, and GAGs were well retained to 81 9.6% (Fig. 1D). Encapsulated cells were viable, with negligible cell death apparent during extrusion and ink gelation by ionic cross-linking, persisting through extended culture in excess of 14 days. The fluorescence intensity of Ki67 of MSCs cultured in 2D condition decreased from days 3 (152.7 13.4) to 14 (29.4 12.9), while maintaining higher intensity of MSCs in 3D construct (such as 211.8 19.4 of PD+3D group and 209.1 22.1 of PD3D group at day 14). And the cell viability in 3D construct was found to be sufficiently high (>80%) when examined on days 3, 7, and 14. The phenomenon of cell aggregate formation and increased cell proliferation implied the excellent cell compatibility of the hydrogel-based construct and promotion of tissue development of 3D architectural guides, which did not depend on the presence or absence of PD (Fig. 1, E and F).

The capability of 3D-printed construct with PD directing MSC to SGs in vitro was investigated. The 3D construct was dissolved, and cells were isolated at days 3, 7, and 14 for transcriptional analysis. Expression of the SG markers K8 and K18 was higher from the 3D construct with (3D/PD+) than without PD (3D/PD); K8 and K18 expression in the 3D/PD construct was similar to with control that MSCs cultured in 2D condition, which implied the key role of PD in SG specification. As compared with the 2D culture condition, 3D administration (PD+) up-regulated SG markers, which indicated that the 3D structure synergistically boosted the MSC differentiation (Fig. 2A).

(A) Transcriptional expression of K8, K18, Fxyd2, Aqp5, and ATP1a1 in 3D-bioprinted cells with and without PD in days 3, 7, and 14 culture by quantitative real-time polymerase chain reaction (qRT-PCR). Data are means SEM. (B) Comparison of SG-specific markers K8 and K18 in 3D-bioprinted cells with and without PD (K8 and K18, red; DAPI, blue; scale bars, 50 m). (C and D) Comparison of SG secretion-related markers ATP1a1 (C) and Ca2+ (D) in 3D-bioprinted cells with and without PD [ATP1a1 and Ca2+, red; 4,6-diamidino-2-phenylindole (DAPI), blue; scale bars, 50 m].

In addition, we tested secretion-related genes to evaluate the function of induced SG cells (iSGCs). Although levels of the ion channel factors of Fxyd2 and ATP1a1 were increased notably in 2D culture with PD and ATP1a1 up-regulated in the 3D/PD construct, all the secretory genes of Fxyd2, ATP1a1, and water transporter Aqp5 showed the highest expression level in the 3D/PD+ construct (Fig. 2A). Considering the remarkable impact, further analysis focused on 3D constructs.

Immunofluorescence staining confirmed the progression of MSC differentiation. At day 7, cells in the 3D/PD+ construct began to express K8 and K18, which was increased at day 14, whereas cells in the 3D/PD construct did not express K8 and K18 all the time (Fig. 2B and fig. S2A). However, the expression of ATP1a1 (ATPase Na+/K+ transporting subunit alpha 1) and free Ca2+ concentration did not differ between cells in the 3D/PD+ and 3D/PD constructs (Fig. 2, C and D). By placing MSCs in such a 3D environment, secretion might be stimulated by rapid cell aggregation without the need for SG lineage differentiation. Cell aggregationimproved secretion might be due to the benefit of cell-cell contact (fig. S2B) (21, 22).

To map the cell fate changes during the differentiation between MSCs and SG cells, we monitored the mRNA levels of epithelial markers such as E-cadherin, occludin, Id2, and Mgat3 and mesenchymal markers N-cadherin, vimentin, Twist1, and Zeb2. The cells transitioned from a mesenchymal status to a typical epithelial-like status accompanied by mesenchymal-epithelial transition (MET), then epithelial-mesenchymal transition (EMT) occurred during the further differentiation of epithelial lineages to SG cells (fig. S3A). In addition, MET-related genes were dynamically regulated during the SG differentiation of MSCs. For example, the mesenchymal markers N-cadherin and vimentin were down-regulated from days 1 to 7, which suggested cells losing their mesenchymal phenotype, then were gradually up-regulated from days 7 to 10 in their response to the SG phenotype and decreased at day 14. The epithelial markers E-cadherin and occludin showed an opposite expression pattern: up-regulated from days 1 to 5, then down-regulated from days 7 to 10 and up-regulated again at day 14. The mesenchymal transcriptional factors ZEB2 and Twist1 and epithelial transcriptional factors Id2 and Mgat3 were also dynamically regulated.

We further analyzed the expression of these genes at the protein level by immunofluorescence staining (figs. S3B and S4). N-cadherin was down-regulated from days 3 to 7 and reestablished at day 14, whereas E-cadherin level was increased from days 3 to 7 and down-regulated at day 14. Together, these results indicated that a sequential and dynamic MET-EMT process underlie the differentiation of MSCs to an SG phenotype, perhaps driving differentiation more efficiently (23). However, the occurrence of the MET-EMT process did not depend on the presence of PD. Thus, a 3D structural factor might also participate in the MSC-specific differentiation (fig. S3C).

To investigate the underlying mechanism of biochemical cues in lineage-specific cell fate, we used quantitative proteomics analysis to screen the ECM factors differentially expressed between PD and dorsal region dermis (DD) because mice had eccrine SGs exclusively present in the pads of their paws, and the trunk skin lacks SGs. In total, quantitative proteomics analyses showed higher expression levels of 291 proteins in PD than DD. Overall, 66 were ECM factors: 23 were significantly up-regulated (>2-fold change in expression). We initially determined the level of proteins with the most significant difference after removing keratins and fibrin: collagen triple helix repeat containing 1 (CTHRC1) and thrombospondin 1 (TSP1) (fig. S5). Western blotting was performed to further confirm the expression level of CTHRC1 and TSP1, and we then confirmed that immunofluorescence staining at different developmental stages in mice revealed increased expression of CTHRC1 in PD with SG development but only slight expression in DD at postnatal day 28, while TSP1 was continuously expressed in DD and PD during development (Fig. 3, A to C). Therefore, TSP1 was required for the lineage-specific function during the differentiation in mice but was not dispensable for SG development.

(A and B) Differential expression of CTHRC1 and TSP1in PD and back dermis (DD) ECM of mice by proteomics analysis (A) and Western blotting (B). (C) CTHRC1 and TSP1 expression in back and plantar skin of mice at different developmental times. (Cthrc1/TSP1, red; DAPI, blue; scale bars, 50 m).

According to previous results of the changes of SG markers, 3D structure and PD were both critical to SG fate. Then, we focused on elucidating the mechanisms that underlie the significant differences observed in 2D and 3D conditions with or without PD treatment. To this end, we performed transcriptomics analysis of MSCs, MSCs treated with PD, MSCs cultured in 3D construct, and MSC cultured in 3D construct with PD after 3-day treatment. We noted that the expression profiles of MSCs treated with 3D, PD, or 3D/PD were distinct from the profiles of MSCs (Fig. 4A). Through Gene Ontology (GO) enrichment analysis of differentially expressed genes, it was shown that PD treatment in 2D condition induced up-regulation of ECM and inflammatory response term, and the top GO term for MSCs in 3D construct was ECM organization and extracellular structure organization. However, for the MSCs with 3D/PD treatment, we found very significant overrepresentation of GO term related to branching morphogenesis of an epithelial tube and morphogenesis of a branching structure, which suggested that 3D structure cues and biochemical cues synergistically initiate the branching of gland lineage (fig S6). Heat maps of differentially expressed ECM organization, cell division, gland morphogenesis, and branch morphogenesis-associated genes were shown in fig. S7. To find the specific genes response to 3D structure cues facilitating MSC reprogramming, we analyzed the differentially expressed genes of four groups of cells (Fig. 4B). The expression of Vwa1, Vsig1, and Hmox1 were only up-regulated with 3D structure stimulation, especially the expression of Hmox1 showed a most significant increase and even showed a higher expression addition with PD, which implied that Hmox1 might be the transcriptional driver of MSC differentiation response to 3D structure cues. Differential expression of several genes was confirmed by quantitative polymerase chain reaction (qPCR): Mmp9, Ptges, and Il10 were up-regulated in all the treated groups. Likewise, genes involving gland morphogenesis and branch morphogenesis such as Bmp2, Tgm2, and Sox9 showed higher expression in 3D/PD-treated group. Bmp2 was up-regulated only in 3D/PD-treated group, combined with the results of GO analysis, we assumed that Bmp2 initiated SG fate through inducing branch morphogenesis and gland differentiation (Fig. 4C).

(A) Gene expression file of four groups of cells (R2DC, MSCs; R2DT, MSC with PD treatment; R3DC, MSC cultured in 3D construct; and R3DT, MSC treated with 3D/PD). (B) Up-regulated genes after treatment (2DC, MSCs; 2DT, MSC with PD treatment; 3DC, MSC cultured in 3D construct; and 3DT, MSC treated with 3D/PD). (C) Differentially expressed genes were further validated by RT-PCR analysis. [For all RT-PCR analyses, gene expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) with 40 cycles, data are represented as the means SEM, and n = 3].

To validate the role of HMOX1 and CTHRC1 in the differentiation of MSCs to SG lineages, we analyzed the gene expression of Bmp2 by regulating the expression of Hmox1 and CTHRC1 based on the 3D/PD-treated MSCs. The effects of caffeic acid phenethyl ester (CAPE) and tin protoporphyrin IX dichloride (Snpp) on the expression of Hmox1 were evaluated by quantitative real-time (qRT)PCR. Hmox1 expression was significantly activated by CAPE and reduced by Snpp. Concentration of CTHRC1 was increased with recombinant CTHRC1 and decreased with CTHRC1 antibody. That is, it was negligible of the effects of activator and inhibitor of Hmox1 and CTHRC1 on cell proliferation (fig. S8, A and B). Hmox1 inhibition or CTHRC1 neutralization could significantly reduce the expression of Bmp2, while Hmox1 activation or increased CTHRC1 both activated Bmp2 expression. Furthermore, Bmp2 showed highest expression by up-regulation of Hmox1 and CTHRC1 simultaneously and sharply decreased with down-regulation of Hmox1 and CTHRC1 at the same time (Fig. 5A). Immunofluorescent staining revealed that the expression of bone morphogenetic protein 2 (BMP2) at the translational level with CTHRC1 and Hmox1 regulation showed a similar trend with transcriptional changes (Fig. 5B). Likewise, the expression of K8 and K18 at transcriptional and translational level changed similarly with CTHRC1 and Hmox1 regulation (fig. S9, A and B). These results suggested that CTHRC1 and Hmox1 played an essential role in SG fate separately, and they synergistically induced SG direction from MSCs (Fig. 5C).

(A and B) Transcriptional analysis (A) and translational analysis (PD, MSCs; PD+, MSCs with 3D/PD treatment; CAPE, MSCs treated with 3D/PD and Hmox1 activator; Snpp, MSCs treated with 3D/PD and Hmox1 inhibitor; Cthrc1, MSCs treated with 3D/PD and recombinant CTHRC1; anti, MSCs treated with 3D/PD and CTHRC1 antibody: +/+, MSCs treated with 3D/PD and Hmox1 activator and recombinant CTHRC1; and /, MSCs treated with 3D/PD and Hmox1 inhibitor and CTHRC1 antibody. Data are represented as the means SEM and n = 3) (B) of bmp2 with regulation of CTHRC1 and Hmox1. (C) The graphic illustration of 3D-bioprinted matrix directed MSC differentiation. CTHRC1 is the main biochemical cues during SG development, and structural cues up-regulated the expression of Hmox1 synergistically initiated branching morphogenesis of SG. *P < 0.05.

Next, we sought to assess the repair capacity of iSGCs for in vivo implications, the 3D-printed construct with green fluorescent protein (GFP)labeled MSCs was transplanted in burned paws of mice (Fig. 6A). We measured the SG repair effects by iodine/starch-based sweat test at day 14. Only mice with 3D/PD treatment showed black dots on foot pads (representing sweating), and the number increased within 10 min; however, no black dots were observed on untreated and single MSC-transplanted mouse foot pads even after 15 min (Fig. 6B). Likewise, hematoxylin and eosin staining analysis revealed SG regeneration in 3D/PD-treated mice (Fig. 6C). GFP-positive cells were characterized as secretory lumen expressing K8, K18, and K19. Of note, the GFP-positive cells were highly distributed in K14-positive myoepithelial cells of SGs but were absent in K14-positive repaired epidermal wounds (Fig. 6, D and E). Thus, differentiated MSCs enabled directed restitution of damaged SG tissues both at the morphological and functional level.

(A) Schematic illustration of approaches for engineering iSGCs and transplantation. (B) Sweat test of mice treated with different cells. Photo credit: Bin Yao, Wound Healing and Cell Biology Laboratory, Institute of Basic Medical Sciences, General Hospital of PLA. (C) Histology of plantar region without treatment and transplantation of MSCs and iSGCs (scale bars, 200 m). (D) Involvement of GFP-labeled iSGCs in directed regeneration of SG tissue in thermal-injured mouse model (K14, red; GFP, green; DAPI, blue; scale bar, 200 m). (E) SG-specific markers K14, K19, K8, and K18 detected in regenerated SG tissue (arrows). (K14, K19, K8, and K18, red; GFP, green; scale bars, 50 m).

A potential gap in MSC-based therapy still exists between current understandings of MSC performance in vivo in their microenvironment and their intractability outside of that microenvironment (24). To regulate MSCs differentiation into the right phenotype, an appropriate microenvironment should be created in a precisely controlled spatial and temporal manner (25). Recent advances in innovative technologies such as bioprinting have enabled the complexities in the matrix design and fabrication of regenerative microenvironments (26). Our findings demonstrated that directed differentiation of MSCs into SGs in a 3D-printed matrix both in vitro and in vivo was feasible. In contrast to conventional tissue-engineering strategies of SG regeneration, the present 3D-printing approach for SG regeneration with overall morphology and function offered a rapid and accurate approach that may represent a ready-to-use therapeutic tool.

Furthermore, bioprinting MSCs successfully repaired the damaged SG in vivo, suggesting that it can improve the regenerative potential of exogenous differentiated MSCs, thereby leading to translational applications. Notably, the GFP-labeled MSC-derived glandular cells were highly distributed in K14-positive myoepithelial cells of newly formed SGs but were absent in K14-positive repaired epidermal wounds. Compared with no black dots were observed on single MSC-transplanted mouse foot pads, the black dots (representing sweating function) can be observed throughout the entire examination period, and the number increased within 10 min on MSC-bioprinted mouse foot pads. Thus, differentiated MSCs by 3D bioprinting enabled exclusive restitution of damaged SG tissues morphologically and functionally.

Although several studies indicated that engineering 3D microenvironments enabled better control of stem cell fates and effective regeneration of functional tissues (2730), there were no studies concerning the establishment of 3D-bioprinted microenvironments that can preferentially induce MSCs differentiating into glandular cells with multiple tissue phenotypes and overall functional tissue. To find an optimal microenvironment for promoting MSC differentiation into specialized progeny, biochemical properties are considered as the first parameter to ensure SG specification. In this study, we used mouse PD as the main composition of a tissue-specific ECM. As expected, this 3D-printed PD+ microenvironment drove the MSC fate decision to enhance the SG phenotypic profile of the differentiated cells. By ECM differential protein expression analysis, we identified that CTHRC1 was a critical biochemical regulator of 3D-printed matrix for SG specification. TSP1 was required for the lineage-specific function during the differentiation in mice but was not dispensable for SG development. Thus, we identified CTHRC1 as a specific factor during SG development. To our knowledge, this is the first demonstration of CTHRC1 involvement in dictating MSC differentiation to SG, highlighting a potential therapeutic tool for SG injury.

The 3D-printed matrix also provided architectural guides for further SG morphogenesis. Our results clearly show that the 3D spatial dimensionality allows for better cell proliferation and aggregation and affect the characteristics of phenotypic marker expression. Notably, the importance of 3D structural cues on MSC differentiation was further proved by MET-EMT process during differentiation, where the influences did not depend on the presence of biochemical cues. To fully elucidate the underlying mechanisms, we first examined how 3D structure regulating stem cell fate choices. According to our data, Hmox1 is highly up-regulated in 3D construct, which were supposed to response to hypoxia, with a previously documented role in MSC differentiation (31, 32). It is suggested that 3D microenvironment induced rapid cell aggregation leading to hypoxia and then activated the expression of Hmox1.

Through regulation of the expression of Hmox1 and addition or of CTHRC1 in the matrix, we confirmed that each of them is critical for SG reprogramming, respectively. Thus, biochemical and structural cues of 3D-printed matrix synergistically creating a microenvironment could enhance the accuracy and efficiency of MSC differentiation, thereby leading to resulting SG formation. Although we further need a more extensive study examining the role of other multiple cues and their possible overlap function in regulating MSC differentiation, our findings suggest that CTHRC1 and Hmox1 provide important signals that cooperatively modulate MSC lineage specification toward sweat glandular lineage. The 3D structure combined with PD stimulated the GO functional item of branch morphogenesis and gland formation, which might be induce by up-regulation of Bmp2 based on the verification of qPCR results. Although our results could not rule out the involvement of other factors and their possible overlapping role in regulating MSC lineage specification toward SGs, our findings together with several literatures suggested that BMP2 plays a critical role in inducing branch morphogenesis and gland formation (3335).

In summary, our findings represented a novel strategy of directing MSC differentiation for functional SG regeneration by using 3D bioprinting and pave the way for a potential therapeutic tool for other complex glandular tissues as well as further investigation into directed differentiation in 3D conditions. Specifically, we showed that biochemical and structural cues of 3D-printed matrix synergistically direct MSC differentiation, and our results highlighted the importance of 3D-printed matrix cues as regulators of MSC fate decisions. This avenue opens up the intriguing possibility of shifting from genetic to microenvironmental manipulations of cell fate, which would be of particular interest for clinical applications of MSC-based therapies.

The main aim and design of the study was first to determine whether by using 3D-printed microenvironments, MSCs can be directed to differentiate and regenerate SGs both morphologically and functionally. Then, to investigate the underlying molecular mechanism of biochemical and structural cues of 3D-printed matrix involved in MSCs reprogramming. The primary aims of the study design were as follows: (i) cell aggregation and proliferation in a 3D-bioprinted construct; (ii) differentiation of MSCs at the cellular phenotype and functional levels in the 3D-bioprinted construct; (iii) the MET-EMT process during differentiation; (iv) differential protein expression of the SG niche in mice; (v) differential genes expression of MSCs in 3D-bioprinted construct; (vi) the key role of CTHRC1 and HMOX1 in MSCs reprogramming to SGCs; and (vii) functional properties of regenerated SG in vivo.

Gelatin (Sigma-Aldrich, USA) and sodium alginate (Sigma-Aldrich, USA) were dissolved in phosphate-buffered saline (PBS) at 15 and 1% (w/v), respectively. Both solutions were sterilized under 70C for 30 min three times at an interval of 30 min. The sterilized solutions were packed into 50-ml centrifuge tubes, stored at 4C, and incubated at 37C before use.

From wild-type C57/B16 mice (Huafukang Co., Beijing) aged 5 days old, dermal homogenates were prepared by homogenizing freshly collected hairless mouse PD with isotonic phosphate buffer (pH 7.4) for 20 min in an ice bath to obtain 25% (w/v) tissue suspension. The supernatant was obtained after centrifugation at 4C for 20 min at 10,000g. The DNA content was determined using Hoechst 33258 assay (Beyotime, Beijing). The fluorescence intensity was measured to assess the amount of remaining DNA within the decellularized ECMs and the native tissue using a fluorescence spectrophotometer (Thermo Scientific, Evolution 260 Bio, USA). The GAGs content was estimated via 1,9-dimethylmethylene blue solution staining. The absorbance was measured with microplate reader at wavelength of 492 nm. The standard curve was made using chondroitin sulfate A. The total COL (Collagen) content was determined via hydroxyproline assay. The absorbance of the samples was measured at 550 nm and quantified by referring to a standard curve made with hydroxyproline.

MSCs were bioprinted with matrix materials by using an extrusion-based 3D bioprinter (Regenovo Co., Bio-Architect PRO, Hangzhou). Briefly, 10 ml of gelatin solution (10% w/v) and 5 ml of alginate solution (2% w/v) were warmed under 37C for 20 min, gently mixed as bioink and used within 30 min. MSCs were collected from 100-mm dishes, dispersed into single cells, and 200 l of cell suspension was gently mixed with matrix material under room temperature with cell density 1 million ml1. PD (58 g/ml) was then gently mixed with bioink. Petri dishes at 60 mm were used as collecting plates in the 3D bioprinting process. Within a temperature-controlled chamber of the bioprinter, with temperature set within the gelation region of gelatin, the mixture of MSCs and matrix materials was bioprinted into a cylindrical construct layer by layer. The nozzle-insulation temperature and printing chamber temperature were set at 18 and 10C, respectively; nozzles with an inner diameter of 260 m were chosen for printing. The diameter of the cylindrical construct was 30 mm, with six layers in height. After the temperature-controlled bioprinting process, the printed 3D constructs were immersed in 100-mM calcium chloride (Sigma-Aldrich, USA) for 3 min for cross-linking, then washed with Dulbeccos modified Eagle medium (DMEM) (Gibco, USA) medium for three times. The whole printing process was finished in 10 min. The 3D cross-linked construct was cultured in DMEM in an atmosphere of 5% CO2 at 37C. The culture medium was changed to SG medium [contains 50% DMEM (Gibco, New York, NY) and 50% F12 (Gibco) supplemented with 5% fetal calf serum (Gibco), 1 ml/100 ml penicillin-streptomycin solution, 2 ng/ml liothyronine sodium (Gibco), 0.4 g/ml hydrocortisone succinate (Gibco), 10 ng/ml epidermal growth factor (PeproTech, Rocky Hill, NJ), and 1 ml/100 ml insulin-transferrin-selenium (Gibco)] 2 days later. The cell morphology was examined and recorded under an optical microscope (Olympus, CX40, Japan).

Fluorescent live/dead staining was used to determine cell viability in the 3D cell-loaded constructs according to the manufacturers instructions (Sigma-Aldrich, USA). Briefly, samples were gently washed in PBS three times. An amount of 1 M calcein acetoxymethyl (calcein AM) ester (Sigma-Aldrich, USA) and 2 M propidium iodide (Sigma-Aldrich, USA) was used to stain live cells (green) and dead cells (red) for 15 min while avoiding light. A laser scanning confocal microscopy system (Leica, TCSSP8, Germany) was used for image acquisition.

The cell-printed structure was harvested and fixed with a solution of 4% paraformaldehyde. The structure was embedded in optimal cutting temperature (OCT) compound (Sigma-Aldrich, USA) and sectioned 10-mm thick by using a cryotome (Leica, CM1950, Germany). The sliced samples were washed repeatedly with PBS solution to remove OCT compound and then permeabilized with a solution of 0.1% Triton X-100 (Sigma-Aldrich, USA) in PBS for 5 min. To reduce nonspecific background, sections were treated with 0.2% bovine serum albumin (Sigma-Aldrich, USA) solution in PBS for 20 min. To visualize iSGCs, sections were incubated with primary antibody overnight at 4C for anti-K8 (1:300), anti-K14 (1:300), anti-K18 (1:300), anti-K19 (1:300), anti-ATP1a1 (1:300), anti-Ki67 (1:300), antiN-cadherin (1:300), antiE-cadherin (1:300), anti-CTHRC1 (1:300), or anti-TSP1 (1:300; all Abcam, UK) and then incubated with secondary antibody for 2 hours at room temperature: Alexa Fluor 594 goat anti-rabbit (1:300), fluorescein isothiocyanate (FITC) goat anti-rabbit (1:300), FITC goat anti-mouse (1:300), or Alexa Fluor 594 goat anti-mouse (1:300; all Invitrogen, CA). Sections were also stained with 4,6-diamidino-2-phenylindole (Beyotime, Beijing) for 15 min. Stained samples were visualized, and images were captured under a confocal microscope.

To harvest the cells in the construct, the 3D constructs were dissolved by adding 55 mM sodium citrate and 20 mM EDTA (Sigma-Aldrich, USA) in 150 mM sodium chloride (Sigma-Aldrich, USA) for 5 min while gently shaking the petri dish for better dissolving. After transfer to 15-ml centrifuge tubes, the cell suspensions were centrifuged at 200 rpm for 3 min, and the supernatant liquid was removed to harvest cells for further analysis.

Total RNA was isolated from cells by using TRIzol reagent (Invitrogen, USA) following the manufacturers protocol. RNA concentration was measured by using a NanoPhotometer (Implen GmbH, P-330-31, Germany). Reverse transcription involved use of a complementary DNA synthesis kit (Takara, China). Gene expression was analyzed quantitatively by using SYBR green with the 7500 Real-Time PCR System (Takara, China). The primers and probes for genes were designed on the basis of published gene sequences (table S1) (National Center for Biotechnology Information and PubMed). The expression of each gene was normalized to that for glyceraldehyde-3-phosphate dehydrogenase and analyzed by the 2-CT method. Each sample was assessed in triplicate.

The culture medium was changed to SG medium with 2 mM CaCl2 for at least 24 hours, and cells were loaded with fluo-3/AM (Invitrogen, CA) at a final concentration of 5 M for 30 min at room temperature. After three washes with calcium-free PBS, 10 M acetylcholine (Sigma-Aldrich, USA) was added to cells. The change in the Fluo 3 fluorescent signal was recorded under a laser scanning confocal microscopy.

Cell proliferation was evaluated through CCK-8 (Cell counting kit-8) assay. Briefly, cells were seeded in 96-well plates at the appropriate concentration and cultured at 37C in an incubator for 4 hours. When cells were adhered, 10 l of CCK-8 working buffer was added into the 96-well plates and incubated at 37C for 1 hour. Absorbance at 450 nm was measured with a microplate reader (Tecan, SPARK 10M, Austria).

Proteomics of mouse PD and DD involved use of isobaric tags for relative and absolute quantification (iTRAQ) in BGI Company, with differentially expressed proteins detected in PD versus DD. Twofold greater difference in expression was considered significant for further study.

Tissues were grinded and lysed in radioimmunoprecipitation assay buffer (Beyotime, Nanjing). Proteins were separated by 12% SDSpolyacrylamide gel electrophoresis and transferred to a methanol-activated polyvinylidene difluoride membrane (GE Healthcare, USA). The membrane was blocked for 1 hour in PBS with Tween 20 containing 5% bovine serum albumin (Sigma-Aldrich, USA) and probed with the antibodies anti-CTHRC1 (1:1000) and anti-TSP1 (1:1000; both Abcam, UK) overnight at 4C. After 2 hours of incubation with goat anti-rabbit horseradish peroxidaseconjugated secondary antibody (Santa Cruz Biotechnology, CA), the protein bands were detected by using luminal reagent (GE Healthcare, ImageQuant LAS 4000, USA).

Total RNA was prepared with TRIzol (Invitrogen), and RNA sequencing was performed using HiSeq 2500 (Illumina). Genes with false discovery rate < 0.05, fold difference > 2.0, and mean log intensity > 2.0 were considered to be significant.

CAPE or Snpp was gently mixed with bioink at a concentration of 10 M. Physiological concentration of CTHRC1 was measured by enzyme linked immunosorbent assay (ELISA) (80 ng/ml), and then recombinant CTHRC1 or CTHRC1 antibody was added into the bioink at a concentration of 0.4 g/ml. The effect of inhibitor and activator was estimated by qRT-PCR or ELISA.

Mice were anesthetized with pentobarbital (100 mg/kg) and received subcutaneous buprenorphine (0.1 mg/kg) preoperatively. Full-thickness scald injuries were created on paw pads with soldering station (Weller, WSD81, Germany). Mice recovered in clean cages with paper bedding to prevent irritation or infection. Mice were monitored daily and euthanized at 30 days after wounding. Mice were maintained in an Association for Assessment and Accreditation of Laboratory Animal Careaccredited animal facility, and procedures were performed with Institutional Animal Care and Use Committeeapproved protocols.

MSCs in 3D-printed constructs with PD were cultured with DMEM for 2 days and then replaced with SG medium. The SG medium was changed every 2 days, and cells were harvested on day 12. The K18+ iSGCs were sorting through flow cytometry and injected into the paw pads (1 106 cells/50 l) of the mouse burn model by using Microliter syringes (Hamilton, 7655-01, USA). Then, mice were euthanized after 14 days; feet were excised and fixed with 10% formalin (Sigma-Aldrich, USA) overnight for paraffin sections and immunohistological analysis.

The foot pads of anesthetized treated mice were first painted with 2% (w/v) iodine/ethanol solution then with starch/castor oil solution (1 g/ml) (Sigma-Aldrich, USA). After drying, 50 l of 100 M acetylcholine (Sigma-Aldrich, USA) was injected subcutaneously into paws of mice. Pictures of the mouse foot pads were taken after 5, 10, and 15 min.

All data were presented as means SEM. Statistical analyses were performed using GraphPad Prism7 statistical software (GraphPad, USA). Significant differences were calculated by analysis of variance (ANOVA), followed by the Bonferroni test when performing multiple comparisons between groups. P < 0.05 was considered as a statistically significant difference.

Supplementary material for this article is available at http://advances.sciencemag.org/cgi/content/full/6/10/eaaz1094/DC1

Fig. S1. Biocompatibility of 3D-bioprinted construct and cellular morphology in 2D monolayer culture.

Fig. S2. Expression of SG-specific and secretion-related markers in MSCs and SG cells in vitro.

Fig. S3. Transcriptional and translational expression of epithelial and mesenchymal markers in 3D-bioprinted cells with and without PD.

Fig. S4. Expression of N- and E-cadherin in MSCs and SG cells in 2D monolayer culture.

Fig. S5. Proteomic microarray assay of differential gene expression between PD and DD ECM in postnatal mice.

Fig. S6. GO term analysis of differentially expressed pathways.

Fig. S7. Heat maps illustrating differential expression of genes implicated in ECM organization, cell division, and gland and branch morphogenesis.

Fig. S8. The expression of Hmox1 and the concentration of CTHRC1 on treatment and the related effects on cell proliferation.

Fig. S9. The expression of K8 and K18 with Hmox1 and CTHRC1 regulation.

Table S1. Primers for qRT-PCR of all the genes.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

Acknowledgments: Funding: This study was supported in part by the National Nature Science Foundation of China (81571909, 81701906, 81830064, and 81721092), the National Key Research Development Plan (2017YFC1103300), Military Logistics Research Key Project (AWS17J005), and Fostering Funds of Chinese PLA General Hospital for National Distinguished Young Scholar Science Fund (2017-JQPY-002). Author contributions: B.Y. and S.H. were responsible for the design and primary technical process, conducted the experiments, collected and analyzed data, and wrote the manuscript. Y.W. and R.W. helped perform the main experiments. Y.Z. and T.H. participated in the 3D printing. W.S. and Z.L. participated in cell experiments and postexamination. S.H. and X.F. collectively oversaw the collection of data and data interpretation and revised the manuscript. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Go here to see the original:
Biochemical and structural cues of 3D-printed matrix synergistically direct MSC differentiation for functional sweat gland regeneration - Science...

Posted in Regenerative Medicine | Comments Off on Biochemical and structural cues of 3D-printed matrix synergistically direct MSC differentiation for functional sweat gland regeneration – Science…

Researchers build the worlds most sophisticated lab model of the human body – Digital Trends

Posted: March 9, 2020 at 2:49 am

In what initially sounds like a blend of Frankenstein and Honey, I Shrunk the Kids, scientists at the Wake Forest Institute for Regenerative Medicine (WFIRM) have built the worlds most advanced model of a human body ever created in a lab. Complete with a system of organs, such as heart, liver and lungs, that function a whole lot like the real thing, the body model was built to replicate as closely as possible the reactions of an actual human body. The difference? Each miniaturized organ is around one-millionth the size of a real-life adult organ.

To create the model, tiny samples of human tissue cells are isolated and engineered into miniature versions of the human organ, Anthony Atala, director of WFIRM, told Digital Trends. They can contain blood vessel cells, immune system cells, and even fibroblasts, the cells in the connective tissue. We designed the integrated platform, or multi-tissue chip, supporting multiple tissue types under a common recirculating fluid. The system, depending on how many tissues it uses, can be designed to fit an area about the size of a deck of cards.

The body doesnt actually look like a body. Instead, its a series of chips and microfluidic devices. The purpose wasnt to build a recognizable miniature human, but rather a testing platform which functions and reacts like the body its based on. For instance, each organ contains blood vessel cells, immune system cells, and fibroblasts, the cells found in connective tissue. The heart beats around 60 times per minute, the lung breathes air from its surroundings, and the liver is used to break down toxic compounds into waste products.

The aim of building this test platform is to better predict and test how a human will react to new drug treatments. This can be used to detect harmful and adverse effects of drugs during the development stage before they enter clinical trials in patients. This can help speed up the process of bringing drugs to market, while also lowering the cost of clinical trials and reducing or even eliminating animal testing.

As part of their research, the team tested the system by using it to screen 10 drugs taken off the market by the U.S. Food and Drug Administration. When these drugs were tested in cell culture, animals and human clinical trials, no negative side effects were identified until they were being widely used by humans. At that point, it was discovered that the drugs could be harmful to people. The system developed at WFIRM was able to detect this toxicity, matching the damage found in humans.

Follow this link:
Researchers build the worlds most sophisticated lab model of the human body - Digital Trends

Posted in Regenerative Medicine | Comments Off on Researchers build the worlds most sophisticated lab model of the human body – Digital Trends

Griffin Canning to receive biological injection in elbow, will be re-evaluated in 3-4 weeks – NBCSports.com

Posted: March 9, 2020 at 2:48 am

The Angels announced that starter Griffin Canning is getting a biological injection in his ailing elbow and will be re-evaluated in 3-4 weeks time. Canning was recently diagnosed with both UCL and joint issues in his pitching elbow.

The phrasing of the announcement is interesting. The word biological generally leads me in two different directions with this sort of injury. Many baseball players have been treated with platelet-rich plasma (PRP) injections for a variety of issues in recent years, but the Angels have also used stem cell injections to try to treat UCL woes.

Andrew Heaney, Garrett Richards and Shohei Ohtani all got stem cell treatments for their elbows. All three also eventually wound up getting Tommy John surgery. Im not willing to go as far as the LA Times article did in condemning the treatments as useless, seeing as a sample size of three is rather small. Theyre also not the only players who have ever been treated with stem cells. CC Sabathia, for instance, got a stem cell injection for his bad knee.

Regardless of what the treatment is or isnt, its a positive sign that Cannings injury wasnt deemed dire enough to immediately merit surgery. Canning isnt going to be ready for Opening Day either way, but if the injection works he may be able to pitch at some point this season. Goodness knows that the Angels rotation needs all hands on deck, even after the team signed both Dylan Bundy and Julio Teheran this winter.

Follow @StelliniTweets

Marc Topkin of the Tampa Bay Times reports that the Rays have initiated contract extension talks with outfielder Austin Meadows. Meadows said, I definitely would be open to something like that. Extension talks havent gotten deep yet, just some initial stuff, as Meadows put it.

Meadows, 24, wont become arbitration-eligible until after the 2021 season and wouldnt become eligible for free agency until after the 2025 season. However, as teams have shown in recent years, signing productive young players to contract extensions can save them a lot of money down the road.

Last season, Meadows broke out, batting .291/.364/.558 with 33 home runs, 89 RBI, 83 runs scored, and 12 stolen bases in 591 plate appearances. Only nine outfielders (min. 500 PA) had a better OPS than Meadows. Seems like a player one would want to continue to play for ones team.

See original here:
Griffin Canning to receive biological injection in elbow, will be re-evaluated in 3-4 weeks - NBCSports.com

Posted in Stem Cell Treatments | Comments Off on Griffin Canning to receive biological injection in elbow, will be re-evaluated in 3-4 weeks – NBCSports.com

Stem Cell Assay Market Competitive Analysis and Forecast 2017-2025 – Monroe Scoop

Posted: March 9, 2020 at 2:48 am

Stem Cell Assay Market: Snapshot

Stem cell assay refers to the procedure of measuring the potency of antineoplastic drugs, on the basis of their capability of retarding the growth of human tumor cells. The assay consists of qualitative or quantitative analysis or testing of affected tissues and tumors, wherein their toxicity, impurity, and other aspects are studied.

With the growing number of successful stem cell therapy treatment cases, the global market for stem cell assays will gain substantial momentum. A number of research and development projects are lending a hand to the growth of the market. For instance, the University of Washingtons Institute for Stem Cell and Regenerative Medicine (ISCRM) has attempted to manipulate stem cells to heal eye, kidney, and heart injuries. A number of diseases such as Alzheimers, spinal cord injury, Parkinsons, diabetes, stroke, retinal disease, cancer, rheumatoid arthritis, and neurological diseases can be successfully treated via stem cell therapy. Therefore, stem cell assays will exhibit growing demand.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=40

Another key development in the stem cell assay market is the development of innovative stem cell therapies. In April 2017, for instance, the first participant in an innovative clinical trial at the University of Wisconsin School of Medicine and Public Health was successfully treated with stem cell therapy. CardiAMP, the investigational therapy, has been designed to direct a large dose of the patients own bone-marrow cells to the point of cardiac injury, stimulating the natural healing response of the body.

Newer areas of application in medicine are being explored constantly. Consequently, stem cell assays are likely to play a key role in the formulation of treatments of a number of diseases.

Global Stem Cell Assay Market: Overview

The increasing investment in research and development of novel therapeutics owing to the rising incidence of chronic diseases has led to immense growth in the global stem cell assay market. In the next couple of years, the market is expected to spawn into a multi-billion dollar industry as healthcare sector and governments around the world increase their research spending.

The report analyzes the prevalent opportunities for the markets growth and those that companies should capitalize in the near future to strengthen their position in the market. It presents insights into the growth drivers and lists down the major restraints. Additionally, the report gauges the effect of Porters five forces on the overall stem cell assay market.

Global Stem Cell Assay Market: Key Market Segments

For the purpose of the study, the report segments the global stem cell assay market based on various parameters. For instance, in terms of assay type, the market can be segmented into isolation and purification, viability, cell identification, differentiation, proliferation, apoptosis, and function. By kit, the market can be bifurcated into human embryonic stem cell kits and adult stem cell kits. Based on instruments, flow cytometer, cell imaging systems, automated cell counter, and micro electrode arrays could be the key market segments.

In terms of application, the market can be segmented into drug discovery and development, clinical research, and regenerative medicine and therapy. The growth witnessed across the aforementioned application segments will be influenced by the increasing incidence of chronic ailments which will translate into the rising demand for regenerative medicines. Finally, based on end users, research institutes and industry research constitute the key market segments.

The report includes a detailed assessment of the various factors influencing the markets expansion across its key segments. The ones holding the most lucrative prospects are analyzed, and the factors restraining its trajectory across key segments are also discussed at length.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=40

Global Stem Cell Assay Market: Regional Analysis

Regionally, the market is expected to witness heightened demand in the developed countries across Europe and North America. The increasing incidence of chronic ailments and the subsequently expanding patient population are the chief drivers of the stem cell assay market in North America. Besides this, the market is also expected to witness lucrative opportunities in Asia Pacific and Rest of the World.

Global Stem Cell Assay Market: Vendor Landscape

A major inclusion in the report is the detailed assessment of the markets vendor landscape. For the purpose of the study the report therefore profiles some of the leading players having influence on the overall market dynamics. It also conducts SWOT analysis to study the strengths and weaknesses of the companies profiled and identify threats and opportunities that these enterprises are forecast to witness over the course of the reports forecast period.

Some of the most prominent enterprises operating in the global stem cell assay market are Bio-Rad Laboratories, Inc (U.S.), Thermo Fisher Scientific Inc. (U.S.), GE Healthcare (U.K.), Hemogenix Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), STEMCELL Technologies Inc. (CA), Cell Biolabs, Inc. (U.S.), and Cellular Dynamics International, Inc. (U.S.).

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read the original:
Stem Cell Assay Market Competitive Analysis and Forecast 2017-2025 - Monroe Scoop

Posted in Stem Cell Treatments | Comments Off on Stem Cell Assay Market Competitive Analysis and Forecast 2017-2025 – Monroe Scoop

"American Journal of Sports Medicine" publishes results of an FDA-approved clinical trial for treating osteoarthritis knee pain – Yahoo…

Posted: March 9, 2020 at 2:48 am

Trial measures safety and efficacy of device and point-of-care cellular therapy to help reduce pain and improve function in osteoarthritic knees

LOUISVILLE, Colo. andNEW ORLEANS andSAN ANTONIO andCHICAGO, March 2, 2020 /PRNewswire/ -- GID BIOannounced today that The American Journal of Sports Medicinepublished resultsof its FDA-approved multi-site, randomized, placebo-controlled Phase IIb clinical trial measuring the safety and efficacy of its SVF-2 device and point-of-care (POC) therapy intended to treat pain and function associated with knee osteoarthritis.

The Phase IIb clinical study was approved by the FDA under an IDE and is the first regenerative cell therapy for osteoarthritis to meet study endpoints using autologous stromal cells from adipose tissue. The cellular therapy for osteoarthritis procedure showed no serious adverse events at two years and a significant reduction in pain at one year. A Phase III pivotal study begins soon at Tulane University School of Medicinewith additional trial sites participating nationwide.

"Publishing this data signifies real science and a breakthrough in regenerative medicine. We've completed a prior safety trial, an FDA-approved Phase IIb trial, and are now beginning a Phase III pivotal trial. Physicians will be able to use the SVF-2 technology to provide a cellular therapy option for patients," said principal investigator for the Phase III trial, Jaime R. Garza, MD, DDS, FACS, Professor of Orthopedic Surgery and Center for Stem Cell Research and Regenerative Medicineat Tulane University School of Medicine. "I am very proud to collaborate with my alma mater, Tulane University, and the School of Medicine's outstanding orthopedic department led by Dr. Felix Savoie, and its worldclass Center for Stem Cell Research and Regenerative Medicine directed by expert cell scientist Dr. Bruce Bunnell," said Dr. Garza.

Dr. Garza is a former NFL player and a Tulane University Athletic Hall of Fame inductee. He is also a clinical professor of plastic surgery and otolaryngology at the University of Texas Health Science Center.

Treatments by clinics using stem cells are under scrutiny by the FDA as its discretionary enforcement period expires in November of this year. The intent is that hundreds of stem cell clinicsnationwide become compliant with FDA regulations, leading to clinical data support of safety and efficacy.

"Our randomized, controlled clinical trial is the first cellular therapy study for osteoarthritis to meet study endpoints using autologous adipose stromal cells for a point-of-care therapy.Eighty-eight percent of subjects responded greater than placebo at one year and reported a median 87% improvement in pain, stiffness and function," said William W. Cimino, Ph.D., CEO of GID BIO. "We are able to isolate and concentrate the right types and numbers of cells to create an effective therapy. We are pleased to begin Phase III trials with Dr. Garza, and to be at the forefront for a cellular therapy option for osteoarthritic knees."

About GID SVF-2 and POC TherapyGID technology has reduced a Good Manufacturing Practice (GMP) cell-processing facility to a single-use disposable device for scalable point-of-care cell processing. The technology uniquely harvests and isolates stromal cells from a patient's own adipose tissue that is then reimplanted by injection in a physician's office in less than two hours. Stromal cells play an essential role in the body's natural healing response, with a dynamic and reactive ability to participate in the healing process. The American Medical Associationgranted GID two new CPT class III codesthat became effective January 2020 as a step toward Medicare reimbursement.

Story continues

About GID BIOGID BIO develops next-generation cellular therapies for degenerative musculoskeletal, dermal, and organ-specific diseases, with the goal of making cellular medicine available to as many people as possible. GID's SVF-2 device and POC therapy harnesses the innate healing power of a patient's own stromal cells. Information on GID's SVF-2 device, biologic cellular implants, POC therapy, osteoarthritis clinical program and GID's pipeline for treating degenerative disease in musculoskeletal conditions includes other indications including, dermal and organs, specifically, wound care and diabetes. Learn more: https://www.HealingIntelligently.com.

AboutTulane University School of MedicineOne of the nation's most recognized centers for medical education,Tulane University School of Medicineis a vibrant center for education, research and public service.Tulane School of Medicineis the second-oldest medical school in the Deep South and the 15th oldest medical school inthe United States.Tulane School of Medicinerecruits top faculty, researchers and students from around the world, and pushes the boundaries of medicine with groundbreaking medical research and surgical advances.Tulaneremains in the forefront of modern medical innovation and is equipping the next generation of medical professionals with the tools to succeed in the rapidly changing future of health care.

About American Journal of Sports MedicineAglobal organization with 3,000 members that generates evidence-based knowledge and promotes emerging research to educate orthopaedic surgeonsand a resource for the orthopaedic sports medicine community, American Journal of Sports Medicine is a peer-reviewed scientific journal, first published in 1972. It is the official publication ofAOSSMfeaturing 14 issues per year. The journal acts as an important forum for independent orthopaedic sports medicine research and education, allowing clinical practitioners the ability to make decisions based on sound scientific information.

Contact:Kellee Johnson, 312-751-3959 or kjohnson@ballastgroup.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/american-journal-of-sports-medicine-publishes-results-of-an-fda-approved-clinical-trial-for-treating-osteoarthritis-knee-pain-301014538.html

SOURCE GID BIO

See the rest here:
"American Journal of Sports Medicine" publishes results of an FDA-approved clinical trial for treating osteoarthritis knee pain - Yahoo...

Posted in Stem Cell Treatments | Comments Off on "American Journal of Sports Medicine" publishes results of an FDA-approved clinical trial for treating osteoarthritis knee pain – Yahoo…

3D beating heart tissue experiment heads to Space Station – UW Medicine Newsroom

Posted: March 9, 2020 at 2:48 am

Note to editors and reporters: Live coverage on NASA Television of the SpaceX CRS-20 cargo launch carrying this experiment is scheduled at 8:30 p.m. EST, 11:30 p.m. PST March 6 and will be replayed twice on March 7. Coverage of the rendezvous with the International Space Station will be at 5:30 a.m. EST Monday, March 8, with installation at 8:30 a.m. All times are subject to change due if weather or launch conditions are unfavorable

MEDIARESOURCES:

Downloads:

Soundbites

Web-embeddable video

Photos of tissue loading

Soundbite Log

Otherresources:

Youtube link

Space exploration can take a toll on the human heart. Astronauts are at risk for changes in their cardiac function and rhythm. To learn how microgravity and other physical forces in space exact their effects on heart muscle, a Tissue Chips in Space project has now been packed and is awaiting launch to the International Space Station.

The experimental equipment consists of small, compact devices, a little bit larger than cell phone cases. The holders contain a row of tiny, 3-D globs of beating heart tissue grown from pluripotent stem cells, generated from human adult cells. The heart muscle tissue is supported between two flexible pillars that allow it to contract freely, in contrast to the rigid constraints of a Petri dish.

The devices also house a novel invention from the University of Washington. It automatically senses and measures the contractions of the heart tissues, and reduces the amount of time the astronauts will need to spend conducting this study.

The flexible pillars contain tiny magnets, explained UW graduate student Ty Higashi, one of the inventors. When the muscle tissue contracts, the position of the embedded magnets changes, and the motion can be detected by a sensor, he said. That information is then sent down to a laboratory on Earth.

This model will recapitulate, on a miniature scale, what might be happening to the architecture and function of heart muscle cells and tissues in astronauts during a space mission.

The project head is Deok-Ho Kim, a professor in bioengineering, who recently joined the Johns Hopkins University faculty in Baltimore. He and co-investigator, Nathan Sniadecki, a professor in mechanical engineering, began this study two years at the UW Medicine Institute for Stem Cell and Regenerative Medicine (ISCRM). Jonathan Tsui, a postdoc in bioengineering, Ty Higashi, a graduate student in mechanical engineering , and other members of the UW project team, continue the cross-country collaboration in Seattle. The team is working with several NASA and National Institutes of Health groups, and researchers at other universities, on this effort.

Sniadecki said that each of the tissues heading to the International Space Center contain about a half million heart cells.

They act like a full tissue, he explained. They contract, they beat and you can actually see them physically shorten in the dish. Were actually able to see little heart beats from these tissues.

The SpaceX shuttle delivering this scientific payload is expected to leave from Cape Canaveral no earlier than 8:50 p.m. PST (11:50 p.m. EST) Friday, March 6. The exact departure schedule depends on the weather and other factors.

Once on board, the experiment will run for 30 days before being returned to Earth for further analysis. A related space-based experiment will follow skyward later, to see if medications or mechanical interventions can offset what the heart muscle endures during extended space missions.

The space program is looking at ways to travel longer and farther, Sniadecki said. To do so, they need to think about protecting their crews. Having treatments or drugs to protect astronauts during their travel would make long term space travel possible.

Guarding against cardiac problems would be especially critical during space travel at distances never attempted before, such as a mission to Mars, said Sniadecki. This opportunity to really kind of push the frontier for space travel is every engineers dream.

He added, We also hope to gather information that will help in preventing and treating heart muscle damage in people generally, as well as in understanding how aging changes heart muscle.

Microgravity is known to speed up aging, and likely influence other cell or tissue properties. Because aging is accelerated in space, studies on the International Space Station is a way to more quickly assess this process over weeks, instead of years.

I think the medicine side of it is extremely helpful on Earth, too, because what we discover could potentially lead to treatments for counteracting aging, Sniadecki said.

This space medicine research project is funded by the National Center for Advancing Translational Sciences and the National Institute of Biomedical Imaging and Bioengineering. This heart tissue study is part of the national Tissue Chips in Space program.

View post:
3D beating heart tissue experiment heads to Space Station - UW Medicine Newsroom

Posted in Stem Cell Treatments | Comments Off on 3D beating heart tissue experiment heads to Space Station – UW Medicine Newsroom

Page 1,109«..1020..1,1081,1091,1101,111..1,1201,130..»